MENARINI INTER.OPERAT.LUXEMBURG SA, LUXEMBURG 1, Avenue de la Gare, L-1611, Luxembourg - Резултати претраге

menarini international operations luxembourg s.a. - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

cogentin

a. menarini new zealand pty ltd - benzatropine mesilate 1 mg/ml - solution for injection - 2 mg/2ml - active: benzatropine mesilate 1 mg/ml excipient: sodium chloride water for injection - cogentin is recommended for all forms of parkinsonism including arteriosclerotic, postencephalitic, idiopathic, as well as medicine-induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. cogentin often is helpful in patients who have become unresponsive to other agents. cogentin is a powerful anticholinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-medicine-induced parkinsonism, partial control of symptoms is usually achieved.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

crestor

a. menarini new zealand pty ltd - rosuvastatin calcium 20.8mg equivalent to rosuvastatin 20mg; - film coated tablet - 20 mg - active: rosuvastatin calcium 20.8mg equivalent to rosuvastatin 20mg excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

crestor

a. menarini new zealand pty ltd - rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg; - film coated tablet - 40 mg - active: rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation